ICH Good Clinical Practice (GCP) for Certified Clinical Research Coordinator (CCRC) Practice Exam

These questions are part of the practice quiz. Start practicing

• Which statement best characterizes the design techniques to avoid bias in clinical trials?
• Which document records treatment allocation and any decoding events and is maintained to support blinding integrity?
• Phase IV objectives may include the assessment of which type of parameters?
• Which statement best describes sponsor obligation in investigator selection?
• Essential Documents for the Conduct of a Clinical Trial are intended to permit evaluation of which aspects?
• What is the purpose of the Subject Identification Code List?
• Before initiating a trial, which approvals must the investigator obtain from the IRB/IEC?
• What does the IRB/IEC conduct with regard to trials?
• Blinding aims to limit conscious and unconscious bias in which areas?
• Which document records the identity, purity, and strength of investigational products to be used in the trial?
• Which statement describes how monitors should handle standard operating procedures?
• Which item is an example of 'Other Observations' in expedited reporting?
• What action should be taken with safety updates and periodic reports?
• Which document specifies the master randomization list?
• Which statement best describes IRB/IEC record retention duration?
• Which statement best describes pre-trial regulatory notification?
• What type of review does the IRB/IEC perform for trials?
• Before informed consent may be obtained, what should the investigator provide?
• Which design is used to facilitate interim analyses in clinical trials?
• In a multicenter trial, which term refers to a committee organized by a sponsor to coordinate the conduct of the trial?
• Who is responsible for retaining trial-related essential documents until the sponsor informs they are no longer needed?
• In Phase II, what is the primary consideration for dosing and regimen?
• Which topic is addressed by the section that covers data integrity and computer software validity?
• Who submits the final report by the investigator to IRB/IEC and, where applicable, to regulatory authorities?
• Before entering an agreement with an investigator, what should the sponsor provide?
• What payment information must be included in the consent?
• IRB/IEC should obtain information about payments to and compensation available to subjects.
• What elements should be included in the Phase IV study design?
• If the sponsor terminates or suspends a trial, what is the investigator's obligation?
• Which topic describes the procedural aspect of submitting expedited ADR reports?
• Which document contains pharmacology, toxicology, and prior human experience data on the investigational product to support human studies?
• What must a monitoring report include after each site visit?
• Which entities should sponsor-specific essential documents be retained for in conformance with regulatory requirements?
• Data capture and processing in a trial can transfer data from the investigator to the sponsor through which media?
• Which of the following is required for an independent data-monitoring committee (IDMC) to effectively operate?
• The sponsor should utilize qualified individuals throughout all stages of the trial for which purpose?
• Who is the person primarily responsible for the proper conduct of the trial at the site?
• Which term describes the set of activities designed to ensure the trial's quality by monitoring compliance and processes, not by data itself?
• May an IRB/IEC invite nonmembers with expertise for assistance?
• In nonclinical pharmacokinetics, which aspect is specifically addressed?
• Which topic outlines how variables are chosen and how data are collected?
• In a Human Pharmacology study, which objective is typically included?
• Which statement best describes data quality requirements for CRFs and required reports?
• When selecting subjects for a Phase IV study, which factors should be considered?
• Which design element helps ensure prognostic factors are balanced across treatment groups?
• What is required regarding the immediate SAE report?
• The subtopic 'Evaluation and Reporting' addresses which aspect of trial data?
• Trials to Show Equivalence or Non-inferiority are divided into two major objective-based categories. What are these two categories?
• Which statement correctly lists the minimum criteria for regulatory reporting of ADRs?
• Why must the protocol specify the principal features of the proposed statistical analysis before starting?
• What is the requirement regarding those who assist with the trial?
• The investigator should comply with the protocol; what is required?
• Where should essential documents be located?
• The CRO should implement which of the following quality processes?
• Phase II primary objective?
• Which option lists the acceptable locations for documenting shipping records for investigational products?
• Surrogate variables are used in indications where they are believed to be reliable predictors of clinical benefit. True or false?
• In emergency enrollment where prior consent is not possible, which statement is NOT correct?
• The document that presents the results and interpretations of a clinical trial is called what?
• All other serious, unexpected ADRs should be filed within how many calendar days after first knowledge?
• Which statement is true about voluntary participation and withdrawal?
• Which statement best captures the requirement for investigator qualifications?
• Data transformation in analysis is used to do what?
• Which statement best describes data capture and processing responsibilities in GCP?
• When a subject withdraws from the trial, which data should be collected?
• Why must the protocol describe dosing schedules and follow-up periods for each treatment group?
• Which activities are included in the IRB/IEC's responsibilities related to meetings?
• Which topic covers the set of subjects to be evaluated and the presentation of data?
• If data are transformed during processing, what must be possible?
• Which item specifies the timing of any planned interim analysis?
• Before starting the trial, how should regulatory submissions be dated?
• Which statement about sponsor responsibility is true?
• What must be provided to the IRB/IEC to obtain its favorable opinion?
• The Marketing Experience section should identify which information?
• Under what guideline condition may abbreviated study reports be acceptable?
• Which statement about Multiple Primary Variables is true?
• What documentation records agreements or significant discussions regarding trial administration, protocol violations, trial conduct, adverse event (AD) reporting?
• What is required before initiating a trial regarding Investigator's Brochure?
• True or false: The initial expedited ADR report must identify the patient, the suspect product, the reporting source, and indicate that the event is serious and unexpected with a reasonable suspected causal relationship.
• Which topic encompasses trial monitoring and interim analyses?
• Which action relates to the investigational product and is a monitor's responsibility?
• In trial documentation, which element identifies the laboratories and other departments involved?
• Surrogate variables are used as reliable predictors of clinical benefit in various indications. Which option matches this idea?
• The physical and mental integrity of the subjects participating in a clinical trial is described as what?
• The sponsor should submit to regulatory authorities all safety updates and periodic reports as required by which of the following?
• What approach should be implemented to assure the quality of every aspect of the trial?
• Which action is explicitly described as a sponsor responsibility related to stability and retention of the investigational product?
• Which component provides the procedures for eliciting reports of and for recording and reporting adverse events and intercurrent illnesses?
• What should be done with trial-related essential documents after the trial when there are still potential marketing applications?
• To document that compensation to subjects for trial-related injury will be available, which locations are listed for documentation?
• The sponsor's system for the disposition of unused IP should ensure what?
• Notification by sponsor and/or investigator to regulatory authorities and IRB/IECs of unexpected serious adverse drug reactions and other safety information is intended for which recipients?
• Phase I is most typically which kind of study?
• Before trial initiation, which body’s approval or favorable opinion is required for the protocol?
• Under Investigator-Adequate Resources, what is emphasized?
• Which statement about the scope of trials is accurate?
• Which element should include the power considerations when determining sample size?
• What recruitment capability must the investigator demonstrate for the trial?
• Which document is used to document the agreement between the investigator and sponsor to the protocol/amendments and the CRF?
• What type of subject identification code should the sponsor use?
• What does Direct Access refer to in the context of clinical trials?
• The plan for which variables are collected and how data are gathered is described by which topic?
• Which statement correctly describes the relationship between Adverse Drug Reaction and Adverse Event?
• Which term refers to an independent data-monitoring committee that may be established by the sponsor to assess at intervals the progress of a clinical trial, the safety data, and the critical efficacy endpoints, and to recommend to the sponsor whether to continue, modify, or stop a trial?
• Which records are required to document the shipment, receipt, disposition, return, and destruction of the investigational product?
• Who is responsible for investigational product accountability at the trial site(s)?
• If a health issue is unrelated to the trial drug, how is it usually categorized?
• What does SUSAR stand for?
• The set of data elements (patient initials, suspected medicinal product, other treatments, details of the suspected ADR, details on the reporter, and administrative details) are used for expedited reports to ensure what?
• Which term best describes documents which individually and collectively permit evaluation of the conduct of a study and the quality of the data produced?
• Which document demonstrates competence of the facility to perform required tests and support reliability of results?
• Which design assigns a sequence of two or more treatments to the same participant, allowing them to serve as their own control?
• When the sponsor discontinues clinical development of an investigational product, who should be notified?
• Which statement best describes an audit in clinical trials?
• Which statement ensures site-level enrollment targets are documented for multisite trials?
• What must be obtained from every subject prior to clinical trial participation?
• Equivalence and non-inferiority trials are divided into two major objective-based categories according to their goals. Which pair describes these categories?
• What is the purpose of the subject identification code list?
• What population is typically used for safety analyses in a GCP-compliant trial?
• When any trial-related duties are transferred to a CRO, what must be specified in writing?
• Freely given informed consent must be obtained from every subject prior to clinical trial participation. Which option reflects a key aspect of this requirement?
• Considerations for the Development Plan emphasize which aspect?
• Why have multiple analysis sets?
• Who should the sponsor designate to advise on trial-related medical questions or problems?
• The sponsor and the investigator/institution should sign the protocol, or an alternative document, to confirm agreement. What action confirms agreement?
• What is required to protect the confidentiality of records that could identify subjects?
• Which party is responsible for the ongoing safety evaluation of the investigational product?
• Expedited safety reports should comply with regulatory requirements and which ICH guideline?
• Which concept is primarily supported by documentation that ensures the integrity and accuracy of trial data?
• The investigator should ensure that the investigational product(s) are used only in accordance with what?
• Which term is a person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or more of a sponsor's trial-related duties and functions?
• The plan for the scope of evaluation in a clinical trial is described by which topic?
• Which statement about the investigational product and protocol is true?
• If prior consent of the trial subject or the subject's legally acceptable representative is not possible, what must the IRB/IEC determine?
• What should be done with the observations and findings of auditors?
• What is true about GMP in relation to investigational product coding and labeling?
• The ethical principles underlying GCP and informed consent trace their origin to which document?
• Which statement best describes sponsor responsibilities related to direct access to source data for monitoring and regulatory inspections?
• Fatal or life-threatening unexpected ADRs must be reported to regulatory authorities within what timeframe after first knowledge?
• Who is the person responsible for the conduct of the clinical trial at a trial site?
• True or False: Phase IV studies begin after drug approval.
• Which parties are responsible for maintaining documentation of regulatory authorities' authorization/approvals/notifications for protocol amendments and other documents?
• For a non-therapeutic trial conducted with consent of the subject's legally acceptable representative, what must the IRB/IEC determine?
• If the trial is blinded, what must the investigator do in the event of any premature unblinding?
• After completion or termination, which set of documents should be retained?
• Which item defines the safety endpoints to be monitored and how they are measured?
• Investigational products should be manufactured, handled, and stored in accordance with which standard?
• What should accompany the communication of new information to the subject to continue participation?
• Interim analyses may lead to early stopping if which conditions are met?
• Why might significance levels be adjusted when multiple analyses are performed?
• Which term is defined as a printed, optical, or electronic document designed to record all protocol-required information to be reported to the sponsor on each trial subject?
• Early nonclinical safety studies should provide information to support which item related to first‑in‑human testing?
• Which term denotes the regulatory framework governing clinical trials of investigational products?
• Financing and insurance provisions should be described where if not addressed in a separate agreement?
• Who maintains the confidential Subject Identification Code List?
• What is a monitor's duty regarding CRF entries and source documents?
• Which entity should retain sponsor-specific essential documents related to the trial?
• Which document confirms the IRB/IEC has reviewed and approved the protocol and includes the official date of approval?
• Which document records the location and identification of retained body fluids/tissue samples if assays need to be repeated?
• Which term is the affirmative decision of the IRB that the trial may be conducted at the site within constraints?
• When should the investigator inform the subject about the need for medical care for intercurrent illness(es)?
• What must be documented regarding data changes to electronic systems?
• What is the primary rationale for using multiple analysis sets?
• When a CRO has assumed trial-related duties, to whom do references to the sponsor apply?
• Which description is required to justify the number of subjects enrolled?
• What should the Summary highlight according to the guidelines?
• Before initiating a clinical trial, how should foreseeable risks and inconveniences be weighed in relation to anticipated benefits for the subject and society?
• What describes the stopping rules or discontinuation criteria for the trial?
• What should be maintained by the IRB/IEC as part of its records?
• Who keeps the Subject Identification Code List, a confidential list of names of all subjects allocated to trial numbers and the ability to reveal identity when needed?
• What is GMP's main aim for IP manufacturing?
• Which scenario would be categorized as an 'Other Observations' item?
• Which data are typically included under safety data in a clinical trial report?
• What documentation verifies the qualifications and eligibility of new investigators and/or sub-investigators to conduct the trial?
• How is subject safety addressed in a GCP trial?
• What is the compilation of clinical and nonclinical data on the investigational products relevant to the study called?
• The role of attending the informed consent process if the subject or legal representative cannot read is associated with which role?
• What best describes the investigator's obligation to IRB/IEC communication?
• Which element should be included regarding patients who stop treatment prematurely in Phase IV trials?
• Which items should the sponsor obtain to confirm IRB/IEC review and operation?
• The investigator should be aware of and comply with which requirements?
• Which statement best describes how an IRB/IEC should operate?
• Which type of trial is designed to provide firm evidence of efficacy or safety?
• Which option best describes the criterion that ensures staff are qualified for their tasks?
• What term describes all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• When a death is reported in a clinical trial, what should the investigator provide to the sponsor and the IRB/IEC?
• Which information is included when discussing storage and handling?
• Which section addresses the reporting of reactions associated with active comparator or placebo treatment?
• Which actions should be reported promptly to the IRB/IEC?
• What is the purpose of assigning unique code numbers to the investigational product(s) and to trial subjects?
• If changes significantly affect the conduct of the trial or increase risk to subjects, how should the investigator report?
• When a subject withdraws due to safety concerns, which data should be documented?
• The IRB/IEC should retain all relevant records for a period of at least how long after completion?
• If a subject withdraws prematurely, what should the investigator do regarding the reasons?
• During trial reviews, special attention should be paid to trials that may include...
• Which statement best describes the sponsor's duty regarding costs of treatment for trial-related injuries?
• Which document provides instructions for handling of investigational products and trial-related materials?
• What should be done about deviations from the protocol?
• Which term refers to a study conducted across more than one site to improve generalizability?
• Who is responsible for submitting the final report by the investigator to IRB/IEC and to regulatory authorities where required?
• Which section should include the description of the population to be studied?
• Under what conditions may expedited review be provided for minor changes in ongoing trials?
• Which statement best reflects a general principle of ICH GCP regarding subject protection?
• 4.5.2 states about deviations without agreement
• What actions should the investigator take to ensure correct use of the investigational product(s) by each subject?
• Before the clinical phase of the trial commences, what should be documented?
• Which aspects should the protocol’s analysis plan cover?
• What is the key purpose of summarizing the clinical database in the report?
• Who is primarily responsible for supplying the investigational product to investigator sites?
• Regarding randomization and unblinding, which statement is correct?
• What is the term for a report of intermediate results and their evaluation based on analyses performed during the course of a trial?
• Informed Consent is defined as
• Where should the financial aspects of the trial be documented?
• How long should sponsor-specific essential documents be retained?
• Under what condition is it recommended to inform the subject's primary physician about participation?
• In describing the investigational product's physical, chemical, and pharmaceutical properties, which item must be included?
• What term describes a clinical trial conducted according to a single protocol but at more than one site?
• Which statement combines the enrollment number and power calculations to justify the trial size?
• What is the primary purpose of the Investigator's Brochure?
• Which statement accurately describes language in the informed consent process regarding waiving legal rights?
• What should the Introduction contain?
• Which item should be described to ensure proper handling, labeling, and traceability of the investigational product during the trial?
• Written procedures for handling the investigational product should include which of the following?
• What is the role of randomization in a clinical trial?
• Which document contains the objective, design, methodology, and statistical considerations of a trial?
• Which item describes the known and potential risks and benefits to human subjects?
• What is the purpose of providing relevant and current scientific information about the investigational product to the investigator?
• Which document records revisions to trial documents that take effect during the trial?
• Who informs the investigator when essential trial documents no longer need to be retained?
• Which statement best describes the role of the investigator regarding monitoring and auditing?
• Regardless of completion, what must be done with clinical trial reports?
• Which statement about access to source data should be included in the protocol or written agreement?
• The Therapeutic Use category is associated with which of the following?
• Which statement is a required characteristic of changes or corrections to CRFs?
• What is the purpose of pre-specifying the statistical analysis in a protocol?
• What is the primary purpose of expedited SUSAR reporting to regulatory authorities?
• Which trial type is an adequately controlled study in which hypotheses are stated in advance and evaluated to provide firm evidence of efficacy or safety?
• What action ensures compliance with GCP regarding oversight?
• What is the retention requirement for essential trial documents after a study ends in an ICH region?
• Which item should be included to provide background by referencing literature and data?
• Before starting a trial, which element is most appropriate to be clearly specified in the protocol?
• The nonclinical pharmacology section should include which of the following?
• Which statement best describes the primary variable in a clinical trial?
• Which concept ensures that trial results are not biased by the method of assigning participants to groups?
• Which item best demonstrates IRB/IEC compliance with GCP and applicable laws?
• What is the primary purpose of a parallel group design?
• What is the stated general expectation about on-site monitoring in trial monitoring guidance?
• Where is the timing of any planned interim analysis described?
• What is the role of an independent data-monitoring committee (IDMC) in a clinical trial?
• What is the primary purpose of a sponsor's audit?
• Which statement best describes the packaging objective for investigational product(s)?
• Which principle guides respect for participants and an appropriate risk-benefit assessment in trials?
• What must be included in the written information provided to subjects regarding payment?
• How should response variables be defined in the protocol?
• Which document updates the Investigator's Brochure during the trial?
• During participation, what must be provided to the subject regarding consent updates?
• What edition-related information is suggested to be provided?
• The sponsor's procedures should include actions for unused investigational product. Which action is correct?
• What information should be provided for the clinical laboratories and other medical or technical departments involved in the trial?
• Which term is a written evaluation by the sponsor's auditor of the results of the audit?
• Which statement is true about trial-related injury is required in the consent?
• Which groups are explicitly included under Special Populations in Phase IV guidelines?
• What should be included in written information for payment?
• Before starting a trial, which statement about IRB approval is correct?
• Which term is an investigational or marketed product, or placebo, used as a reference in a clinical trial?
• Which item is NOT a required element of IRB/IEC confirmation of review?
• Prior to initiating a trial, what should be defined, established, and allocated?
• If deviations from the original statistical plan occur, what is required for documentation?
• If the sponsor discontinues clinical development of an investigational product, how long should sponsor-specific essential documents be retained?
• Which term describes all noxious and unintended responses to a medicinal product related to any dose?
• Which action ensures data can be recovered in case of system failure?
• Who may inspect trial records as part of QA and regulatory oversight?
• What does the Introduction convey about the product's identity and research rationale?
• If a trial is prematurely terminated or suspended, what information should be promptly communicated?
• What must be specified in the protocol regarding access to source data and documents?
• What must be maintained for the randomization process and potential code-breaking?
• Which statement best describes the 'Considerations for Individual Clinical Trials' category?
• Which option best describes what the introduction to nonclinical pharmacology should include?
• What is the written report from the monitor to the sponsor after each site visit or other trial-related communication called?
• Which statement best reflects the Marketing Experience section?
• Which of the following should the IRB/IEC obtain to verify investigator qualifications?
• What should the investigator maintain regarding significant trial-related duties?
• Which document lists all subjects enrolled and is kept confidential for potential follow-up?
• Which document provides the written information given to trial subjects to support informed consent?
• Which statement best describes why trial records are maintained?
• What is required when transferring any trial-related duty to a CRO?
• Which term refers to the original documents, data, and records used during a clinical trial?
• Which records document the qualifications of investigators and sub-investigators?
• What information describes the expected duration of subject participation and the sequence of all trial periods?
• When do Phase IV studies occur in the drug development lifecycle?
• What is the purpose of documenting retained body fluids/tissue samples?
• Which statement about the Subject Screening Log is true?
• Under what circumstances might multiple primary variables be appropriate?
• Which term refers to the judgement and/or advice provided by an Independent Ethics Committee (IEC)?
• What is required before enrolling any subject in a trial?
• Which criterion justifies early termination of a trial?
• To document informed consent, which documents are described as used?
• Which elements are included in the subject withdrawal criteria and procedure?
• Which statement about the Independent Data Monitoring Committee (IDMC) is true?
• During participation, what must be provided to the subject when updates to consent are made?
• Which aspect must be described about the investigational product to ensure proper administration and traceability?
• Phase II typically starts with initiation of studies in which population?
• Where should signature sheets be maintained?
• Which statement best describes the documentation of trial finances?
• Upon completion of the trial, what should the investigator do?
• Which term is a description of a study described as a trial conducted in humans that is produced by integrating clinical and statistical descriptions in a single report?
• Which statement best describes the efficacy assessment in a clinical trial?
• The location(s) where trial-related activities are actually conducted are referred to as what?
• Which document includes original records related to the trial, to medical treatment, and history of the subject and substantiates the trial data?
• During and after participation, what is the investigator's obligation regarding adverse events and significant laboratory values?
• What should be done regarding patient compliance in a trial?
• The responsibility for medical care and medical decisions for trial subjects rests with which professional?
• The Development Plan considerations address which of the following aspects?
• Which statement best describes the sponsor's responsibilities for the investigational product?
• The monitor's responsibilities include ensuring that the trial is conducted and documented properly by carrying out activities when relevant. This is described in which section?
• What is the recommended timing for reporting SAEs to the sponsor per GCP?
• What role do data monitoring committees (DMC/DSMB) play in relation to the clinical database?
• In a trial with more than one presentation or use, how should safety reporting be conducted?
• On request from monitor, auditor, IRB/IEC, or regulatory authority, what should the investigator do?
• What type of trial is designed to show that the investigational product is equivalent to, or not worse than, a reference treatment?
• Before initiating the clinical trial(s), what should the sponsor submit to the appropriate authority(ies)?
• What should be described when defining response variables?
• Progress Report: How often should the investigator submit written summaries of trial status to the IRB/IEC?
• Should records identifying the subject be kept confidential and identity remain confidential when results are published?
• Which document is used to determine the expectedness of an ADR?
• What must be obtained before initiating any protocol deviation?
• What topics should be included in the Effects in Humans: Introduction with respect to pharmacokinetics data?
• What entity is responsible for deciding whether a reaction in a trial using an active comparator or placebo should be reported to the manufacturer or to regulatory agencies?
• The design of case report forms (CRFs) in multicenter trials should capture what?
• Who may request evidence of the investigator's qualifications?
• Which statement correctly describes the Full Analysis Set?
• When must pharmacokinetic (PK) impact studies be available?
• Which type of trial is primarily intended to provide firm evidence of efficacy or safety?
• Which term describes an investigator assigned the responsibility for the coordination of investigators at different centers participating in a multicenter trial?
• What is the primary purpose of documenting normal values/ranges for medical, laboratory, or technical procedures included in the protocol?
• Who is primarily responsible for summarizing safety data in the clinical report?
• Which statement about auditors is correct?
• Which scenario best illustrates the scope of stopping rules within a trial protocol?
• How often should the IRB/IEC conduct continuing review of ongoing trials, considering risk level?
• Data transformation is typically used to?
• The method and manner of compensation to trial subjects should...
• In a dose-ranging program, what is the primary objective?
• What is the primary purpose of QA/QC systems in GCP?
• What information should be provided for the physician or dentist responsible for site medical decisions when this person is not the investigator?
• According to GCP guidance, who should the sponsor utilize to supervise the overall conduct of the trial, handle statistics, verify data, conduct statistical analysis, and prepare trial reports?
• Who should permit monitoring and auditing by the sponsor, and inspections by regulatory authorities?
• When may the investigator implement a deviation without prior IRB/IEC approval?
• Which topics are encompassed by the Estimation, Confidence Intervals and Hypothesis Testing section?
• Which statement accurately describes the use of documentation for all subjects who began trial procedures?
• Which statement is true about confidentiality and ongoing information for trial subjects?
• What is the required documentation for informed consent?
• Which statement best describes the handling of changes or corrections to the CRF?
• Which statement about payments to trial subjects is correct?
• In Phase I, which objective is described as Estimation of initial safety and tolerability?
• What determinations should the sponsor make for the investigational product regarding storage?
• Which category requires reporting within 15 calendar days after first knowledge?
• Which term is defined as a standard for the design, conduct, performance, monitoring, auditing, recording, analyses, and reporting of clinical trials that provides assurance that the data and reported results are credible and accurate, and that the rights, integrity, and confidentiality of trial subjects are protected?
• Labeling of investigational product(s) must comply with what?
• Where are the analysis sets typically defined in a clinical trial protocol?
• What form should the Investigator's Brochure information take?
• Which item is not included in the Introduction content?
• What should the investigator ensure about staffing and facilities for the trial?
• Which topic describes the evaluation of safety and tolerability?
• Which statement best describes the focus of the Development Plan Considerations?
• Which document confirms that investigational products have been used according to the protocol?
• Which statement best describes what is involved in establishing the IRB/IEC's formal basis?
• If a deviation is implemented to eliminate an immediate hazard, what must be done?
• Dose-response relationships can be evaluated in which phases of development?
• Which design typically involves conducting trials at more than one site to gather diverse data?
• Phase III is intended to provide an adequate basis for what?
• Which element describes the methods and timing for assessing, recording, and analyzing efficacy parameters?
• Which term refers to the official review of documents, facilities, and records by a regulatory authority?
• Which statement is not described as part of the Investigator's Brochure's purpose?
• How should the language of the consent information be written?
• Which design approaches testing two or more treatments by using different combinations and evaluating potential interactions?
• Which statement expresses the requirement that participant safety and well-being take precedence over scientific or societal interests?
• Does the protocol specify whether and how replacement of withdrawn subjects may occur?
• Which body must approve the inclusion of subjects for whom consent may be provided by a legally acceptable representative in non-therapeutic trials?
• Which principle places the rights, safety, and well-being of the trial subjects as the most important considerations, taking precedence over science and society?
• The primary aim of protecting clinical trial subjects is to ensure what?
• Which information must be specified about treatments for each trial group?
• What should the analysis plan consider regarding early withdrawals and protocol violations?
• Which factor is essential when selecting auditors?
• Which statement best describes the investigator's obligation to communicate with the IRB/IEC?
• Which topic focuses on the methods for statistical evaluation in a trial?
• When should the written informed consent form and any other written information be revised, and what approval is required before use?
• Which topic addresses the integrity of data and the validity of computer software used in data handling?
• Global assessment variables are typically implemented as what kind of scale?
• Which element defines how safety data are collected and reported?
• Which of the following is an objective of the ICH safety guidance?
• Which document demonstrates that regulatory authorities have authorized/approved/notified the protocol prior to initiation of regulatory requirements?
• During the trial, to whom should the investigator provide documents subject to review?
• An adverse reaction, the nature or severity of which is not consistent with the applicable product information, is known as what?
• Which documentation should the IRB/IEC consider to assess the investigator's qualifications for a proposed trial?
• Which term is a declaration of confirmation by the auditor that an audit has taken place?
• Which design evaluates two or more treatments simultaneously by varying combinations of treatments?
• Which document records that trial procedures were reviewed with the investigator and the investigator's trial staff?
• What statement best describes the relationship between exploratory and confirmatory trials?
• Which document records that amendments and/or revisions have been subject to IRB/IEC review and were given approval/favorable opinion, and identifies the version number and date of the documents?
• If a subject cannot read, what is required during the consent discussion?
• What does the IRB/IEC determine as appropriate for continuing review?
• Which two techniques are described as measures to minimize bias in the trial?
• What is the primary purpose of protection of clinical trial subjects under GCP?
• Essential documents retention extension: It may be longer if required by what?
• In GCP trials, what level of significance is commonly used for hypothesis testing?
• Which items must the IRB/IEC promptly notify the investigator in writing?
• Development Methodology in the context of the development plan covers what?
• Phase IV studies may involve which of the following activities?
• To document the existence of the subject and substantiate integrity of trial data collected; to include original documents related to the trial, to medical treatment, and history of subject
• Which statement correctly describes sponsor auditing procedures?
• According to the material, the Investigator's Brochure serves to document which of the following?
• What is the sponsor's responsibility regarding site access for monitoring, auditing, and inspection?
• What follow-up is advised for subjects who withdraw from treatment?
• Group sequential designs are used to facilitate the conduct of interim analyses.
• Global Assessment Variables measure what in a clinical trial?
• Which two roles are typically responsible for safety data collection and reporting in a trial?
• Which factors determine the extent and nature of monitoring?
• When may regulatory authorities access audit reports if not routinely requested?
• What must investigators maintain to demonstrate that subjects were provided the doses specified by the protocol and to reconcile all investigational product(s) received from the sponsor?
• Which document serves as the formal record that a subject has given informed consent and is used as part of trial data?
• What should the analysis plan address?
• Individuals whose willingness to volunteer in a clinical trial may be unduly influenced by expectation, benefits associated with participation, or hierarchical retaliation are referred to as what?
• Interim or annual reports are provided to which parties?
• The sponsor's audit plan and procedures should be guided by which factors?
• Who must sign and date the written informed consent prior to participation?
• As part of the investigator's written application to the IRB/IEC, what must be provided?
• Which element describes how long subjects participate and when follow-up occurs, including subsequent trial periods?
• Which topic discusses an integrated summary of trial results?
• What must be included about the reporting source in expedited ADR reports?
• The sponsor should utilize qualified individuals throughout all stages to do what?
• Which term is the formal written summary of the audit findings?
• Which item ensures that references to literature and data relevant to the trial are included?
• Which topic is specifically addressed under pharmacokinetic studies?
• Which statement best describes how missing, unused, and spurious data should be handled in a GCP trial?
• Which requirement ensures that a trial's conduct aligns with approved procedures?
• In GCP, how are efficacy data distinguished from safety data?
• Which statement about non-therapeutic trials with LAR consent is NOT correct?
• For a fatal or life-threatening ADR, the initial notification must include which of the following elements?
• Investigators must permit which activities?
• Which statement about source data verification is correct?
• What do you call a clinical trial conducted according to a single protocol but at more than one site?
• Which description best matches an Impartial Witness in clinical trials?
• Which term describes a systematic and independent examination of trial related activities and documents to determine whether they were conducted and the data were recorded, analyzed and accurately reported according to the protocol, sponsor's SOPs, GCP, and applicable regulatory requirements?
• Who is responsible for the medical care and medical decisions for trial subjects?
• Which statement best describes the Per Protocol Set?
• How should the sponsor inform investigators about the need for record attention?
• Which is a written description of a change to or formal clarification of a protocol?
• Which action should the investigator take if a trial is prematurely terminated or suspended?
• If IRB/IEC requires changes to the protocol or consent, what should the sponsor obtain?
• Which element describes the trial's design and includes a schematic diagram of its design, procedures, and stages?
• Which statement best describes Quality Assurance in clinical trials?
• Which statement best describes the design of a trial in terms of scientific quality?
• During the clinical conduct of the trial, which category includes all documents required in the initial phase plus the following?
• In Phase I, pharmacokinetic studies may be conducted in which subjects?
• Which topic specifically covers issues arising when therapy is blinded during a trial?
• Regarding structural similarities to other known compounds, which statement is appropriate?
• Ethical considerations in a clinical trial include which of the following?
• What should the sponsor provide when regulatory requirements require coverage for trial-related injuries?
• Which term is used for an ADR that is not described in the product labeling or Investigator's Brochure?
• Which term best describes the process of performing a formal review to ensure compliance with the protocol and SOPs?
• Which topic involves evaluating the safety and tolerability of a therapy in a clinical trial?
• How should clinical study reports be documented?
• What is the role of an Independent Data-Monitoring Committee (IDMC)?
• Outside consultant(s) may be appointed for what purpose?
• Which statement best describes the close-out documentation requirements?
• What document records site visits by, and findings of, the monitor?
• Who should provide Curriculum Vitae and other documents evidencing qualifications of investigators and sub-investigators?
• The investigator should be thoroughly familiar with the appropriate use of the investigational products as described in which sources?
• Which definition best describes a Serious Adverse Event (SAE) in GCP?
• Which term describes a procedure in which one or more parties to the trial are kept unaware of the treatment assignment?
• What is the purpose of Information Given to Trial Subject -- Informed Consent Form?
• What is the requirement for retention and archiving of trial records?
• Which item is NOT typically considered a key data element for expedited reports of serious adverse reactions?
• Which term is defined as any untoward medical occurrence in a patient or trial subject administered a pharmaceutical product, regardless of causal relation?
• Which term describes the ongoing evaluation of trial progress and subject safety by a monitor, and the reporting of findings to the sponsor?
• During the trial, which entity monitors safety data continuously?
• SUSARs require expedited reporting to regulatory authorities within what general timeframe?
• What does the term 'Expectedness' refer to in the context of an ADR?
• Randomization provides a sound statistical basis for the evaluation of treatment effects. Which option best expresses this?
• Which term refers to original documents, data, and records?
• What factors influence the sample size in a clinical trial?
• Who should sign off on changes or corrections to CRFs made by sponsor-designated representatives?
• Who is permitted to vote on trial-related matters within an IRB/IEC?
• In trials where enrollment can occur only with the consent of the subject's legally acceptable representative, if the subject is capable, what should occur regarding consent?
• Which Phase I consideration relates to clearance and potential drug-drug interactions?
• The brochure's purpose supports investigators in assessing risk-benefit for which aspect?
• Which statement best reflects the expected time frame for conducting and completing the trial?
• What should the Investigational Brochure describe regarding risks and monitoring?
• If a publication policy is not addressed in a separate agreement, what should be established regarding publication of trial results?
• What must be provided to show the investigator's qualifications?
• Which term describes the process of assigning trial subjects to treatment or control groups using chance to reduce bias?
• Accrual rate refers to which aspect of a trial?
• Which statement best describes the broad aim of the development plan for a new drug?
• Which statement describes ensuring information for trial personnel about protocol and investigational products?
• Which items should be included in the investigational product accountability records?
• If the investigator terminates or suspends a trial without prior agreement of the sponsor, what is required?
• Which statement best describes how all clinical trial information should be treated?
• What is the primary purpose of allocating trial-related duties and functions before trial start?
• What is documented by Advertisement for Subject Recruitment?
• Early nonclinical safety studies should provide information to support which of the following, EXCEPT?
• Which term is used to describe a method where a participant or investigator is unaware of the treatment assignment?
• Which item summarizes findings from nonclinical studies and clinical trials relevant to the trial?
• Which trial design randomizes participants to two or more arms, each arm receiving a different treatment?
• What term refers to the act of overseeing the progress of a clinical trial and ensuring it is conducted, recorded, and reported in accordance with the protocol, SOPs, GCP, and regulatory requirements?
• During the trial, what should the investigator provide to the IRB/IEC?
• All investigators must conduct the trial in strict compliance with which directive?
• Which documents guide the trial design, protocol, and conduct?
• If the Investigator's Brochure is updated during the trial, what should be done?
• What documentation should the sponsor obtain regarding IRB/IEC re-approvals or reevaluations?
• In SAE reporting, how should subjects be identified?
• Which statement about formulation details is correct?
• Which topic covers subgroups, interactions, and covariates?
• Which item must be included in the informed consent discussion and form? 4.8.9 content about risks and benefits etc.
• What documentation certifies the identity, purity, and strength of investigational products to be used in the trial?
• Under what circumstance may the IRB/IEC require that more information be given to subjects beyond standard guidance?
• When new safety information becomes available during a trial, who must be informed of this information?
• Which statement best describes the CRO's QA/QC duties?
• Phase IV objectives may include which of the following?
• The Introduction should provide the general approach to what?
• The plan outlining what aspects of a trial are to be evaluated is described by which topic?
• Under which circumstances may protocol deviations or changes be initiated without prior IRB/IEC approval?
• Who should vote on trial-related matters?
• How should the investigational product(s) be stored?
• Data handling and record keeping in a GCP trial should ensure which principle?
• Where are analysis sets defined in a protocol?
• Which term represents all information in original records and certified copies necessary for reconstruction and evaluation of the trial?
• Publication policy in GCP should be addressed where if not in a separate agreement?
• To preserve confidentiality, which identification method should be used in SAE reporting?
• Which bodies may perform inspections of trial data and sites as part of QA activities?
• Which statement best describes the purpose of subject inclusion criteria in a clinical trial?
• Adverse events reporting timeframe?
• Which best describes how safety findings should be presented in the final report?
• What must QA/QC ensure about data?
• Which activity describes the IRB/IEC's scheduling and notification responsibilities?
• What should the investigator do for any deviation from approved protocol?
• In a non-therapeutic trial, who normally must give consent and sign the written informed consent, unless an exception is justified?
• Which term refers to any investigation in human subjects intended to discover or verify the clinical, pharmacological and/or other pharmacodynamic effects of an investigational product, and/or to identify adverse reactions, and/or to study absorption, distribution, metabolism, and excretion of an investigational product with the object of ascertaining its safety and/or efficacy?
• Who should be responsible for all trial-related medical decisions?
• What must the sponsor verify regarding a subject's consent for direct access to original medical records?
• Which statement best describes subject exclusion criteria?
• When a trial is terminated or suspended, which parties should be informed promptly and given reasons?
• What is the primary aim of trial monitoring?
• Which event would not typically be classified as a Serious Adverse Event?
• Which are the objectives associated with Therapeutic Exploratory studies?
• Which of the following describes recommended characteristics of an IRB/IEC?
• Under monitoring guidance, which statement correctly describes the 5.18.1 purpose?
• IRB/IEC procedures should be...
• Which of the following is explicitly a Phase IV subcategory?
• After an SAE is reported immediately, what should follow?
• Who should retain sponsor-specific essential documents pertaining to the trial?
• Sample size adjustment is used to account for what during a trial?
• Which document confirms the formal written agreement among the involved parties before the study begins?
• In a crossover design, what is a key benefit for treatment comparisons?
• Which statement best describes subject protection focus in ICH GCP general principles?
• Which design typically involves conducting trials across multiple research sites?
• Which item provides the description of the population to be studied in the context of Background Information?
• In emergency situations where prior consent is not possible, which statement is correct?
• Who bears responsibility for implementing and maintaining quality assurance and quality control systems in a trial?
• In multi-center trials, who is responsible for organization and selection of coordinating investigator(s)?
• What document provides detailed, written instructions to achieve uniformity of performance of a specific function?
• What primarily determines the sample size of a clinical trial?
• Exploratory trials should have clear and precise objectives.
• Which combination best describes the data transfer media used in data capture and processing?
• Upon completion, what should be provided to the IRB/IEC?
• Which term describes documentation that allows reconstruction of the course of events?
• Which term refers to adherence to trial-related requirements and Good Clinical Practice (GCP) requirements?
• Essential Documents are those that demonstrate compliance with which standards?
• Which documents should the IRB/IEC obtain from the investigator?
• Which statement about exploratory trials is true?
• What form must agreements between the sponsor and investigator or institution take?
• Which document confirms that the site is suitable for the trial?
• What term describes a unique identifier assigned by the investigator to each trial subject to protect the subject's identity and used in lieu of the subject's name?
• A transfer of ownership of trial data should be reported to which entity?
• What document records revisions to normal values/ranges used for medical, laboratory, or technical procedures included in the protocol?
• If the IRB/IEC withdraws or suspends approval, what should be done?
• What distinguishes an Adverse Drug Reaction (ADR) from a general Adverse Event (AE)?
• What is required when protocol deviations occur?
• What should be signed to confirm agreement to the protocol?
• What documentation should be provided to sponsor and IRB/IEC if termination occurs without sponsor agreement?
• Which statement best describes the tone of the Investigator's Brochure?
• Which document identifies subjects who entered pre-trial screening?
• Which activity is a monitor's responsibility to ensure the trial is conducted and documented properly?
• In superiority trials, which approach most convincingly demonstrates efficacy?
• Which body may be established by the sponsor to assess progress, safety data, and critical efficacy variables and to recommend continuation, modification, or termination?
• What should the protocol specify to minimize bias?
• What should the Summary emphasize?
• Which topic is addressed by procedures for monitoring subject compliance?
• Which document would you reference to verify the IRB/IEC approval status and its date/version information?
• In electronic trial data handling, which statement reflects a requirement to protect data integrity?
• If monitoring or auditing identifies serious and persistent noncompliance, what should the sponsor do?
• What expenses information must be included in the consent?
• What is the role of the investigator in IRB/IEC deliberations?
• Which records document that consent is obtained in accordance with GCP and protocol and dated prior to participation of each subject in trial, and also document direct access permission?
• Under what circumstances are interim results appropriate to include in the clinical study report?
• If a single primary variable cannot be selected from multiple measurements, what strategy is recommended?
• If a trial-related duty is not transferred to the CRO, who retains that duty?
• Nonclinical studies focus on which areas to support initial human dose?
• In blinded trials, what should the coding system include?
• How often should investigators check that each subject is following the instructions for using the investigational product?
• In a trial protocol, which elements must be explicitly defined as the primary and secondary outcomes to be measured?
• What is the primary purpose of expedited safety reports in the ICH framework?
• Which document is used to document signatures and initials of all persons authorized to make entries and/or corrections on case report forms?
• 4.5.4 describes what about deviations to eliminate immediate hazards?
• In the Phase IV framework, which category specifically covers Studies of Drug Metabolites?
• What does statistically controlled sampling in monitoring pertain to?
• Which of the following best describes what the IRB/IEC review should encompass?
• Who is responsible for initiating, managing, and financing a clinical trial?
• The sponsor should update the Investigator's Brochure in which scenario?
• Who may vote or provide their opinion in IRB/IEC deliberations and discussions?
• Which statement best describes a requirement of informed consent?
• Which of the following describes the Per Protocol Set's components?
• Which bodies have the power to regulate clinical trials?
• Which statement supports sample size justification?
• Which statement correctly describes expedited review for minor changes?
• 4.5.1 summarizes which concept?
• Which description best captures the essential focus when selecting a dose range in development planning?
• Which statement accurately describes the staffing and facilities requirement?
• An individual who participates in a clinical trial, either as a recipient of the investigational product or as a control, is called what?
• Which statement describes the purpose of keeping essential documents post-trial?
• Which document covers the decoding procedures for blinded trials?
• How should study reports be prepared in relation to guidelines?
• What is the purpose of adjusting significance and confidence levels?
• When planning trials, what should the sponsor ensure regarding safety and efficacy data?
• Which document describes the written description of a change to the protocol?
• Blinding is intended to limit bias arising from knowledge of treatment in which aspects?
• In the Phase IV design, what aspect relates directly to safety monitoring?
• During Monitoring Procedures, after each site visit, what must a monitoring report include?
• Which document records the final accounting of investigational products at the site?
• The sponsor should maintain records for which activities related to the investigational product's lifecycle?
• What documentation describes shipment dates, batch numbers, and method of shipment for investigational products to enable tracking and accountability?
• Which adverse drug reactions (ADRs) require expedited reporting to all concerned investigators/institutions, IRBs/IEC(s) where required, and regulatory authorities?
• Deviations from or changes to the protocol should not be initiated without prior written IRB/IEC approval except in which circumstances?
• Which records changes, additions, or corrections made to the Case Report Form after initial data were recorded?
• What must be described and justified regarding the investigational product?
• Medical expertise is applied in which area according to the guideline?
• Which element details the type and duration of the follow-up of subjects after adverse events?
• Who should be informed of storage determinations?
• Which statement about Categorized Variables is correct?
• Which statement is included to confirm compliance with protocol and regulatory requirements?
• What term describes biomedical studies not performed on human subjects?
• If a sponsor transfers trial-related duties to a CRO, who retains ultimate responsibility for the quality and integrity of the trial data?
• Why should the Investigator's Brochure be updated?
• Which term is a committee that a sponsor may organize to coordinate the conduct of a multicenter trial?
• Which document demonstrates compliance with labeling regulations and the appropriateness of instructions provided to subjects?
• The extent and nature of monitoring should be based on considerations such as objective, purpose, design, complexity, blinding, size, and endpoints. True or False?
• What is required regarding follow-up information for expedited ADR reports?
• What term describes the act by a regulatory authority of conducting an official review of documents, facilities, records, and related resources for the trial?
• A unique identifier assigned by the investigator to protect subject identity when reporting trial data is called what?
• Which statement should be included in the statistical plan to describe interim analysis timing?
• Should changes in inclusion and exclusion criteria remain constant during recruitment?
• Which term refers to the operational techniques and activities undertaken within the quality assurance system to verify that requirements for quality of trial-related activities have been fulfilled?
• In trial planning, which element must be clearly specified in a protocol before the trial begins?
• What information must be described about investigational products?
• Which design is defined as evaluating two or more treatments simultaneously through varying combinations and possible interactions?
• In multisite trials, what should be specified regarding enrollment?
• Which statement best describes the purpose of Any Other Written Information provided to trial subjects?
• Which statement best defines an Adverse Event (AE) in a clinical trial?
• Which role is an individual who both initiates and conducts a trial and under whose immediate direction the investigational product is administered to a subject?
• Which option best describes the Introduction's comprehensive content regarding the product?
• Who is responsible for the accuracy of the clinical database summary?
• Phase III primary objective?
• What does blinding accomplish in a trial?
• Non-therapeutic trials conducted with consent of a legally acceptable representative should be conducted under which condition?
• Which document records the destruction of unused investigational products?
• What is the recommended approach when presenting conclusions about efficacy in the summary?
• Which term describes adherence to all the trial-related requirements, Good Clinical Practice (GCP) requirements, and the applicable regulatory requirements?
• What is the purpose of reviewing the amount and method of payment to subjects?
• Which statement describes a composite variable?
• Which statement is true about familiarization with the investigational product use?
• Which document identifies the IRB/IEC approval (dated and documented) of trial related documents?
• Which information must be provided for the qualified physician or dentist responsible for all trial-site medical decisions if the physician is not the investigator?
• Which entities should the sponsor promptly notify about findings that could affect subject safety, trial conduct, or the continued favorable opinion of the IRB/IEC?
• Which topic is dedicated to the act of reporting study results?
• What is required to ensure timely delivery of the investigational product to investigators?
• One of the objectives of the ICH E8 document is to present an overview of the ICH clinical safety and efficacy documents and facilitate access to guidance pertinent to clinical trials. Which option best captures this objective?
• What should be documented regarding the responsibilities of coordinating and participating investigators before starting the trial?
• Which term describes signs or diseases temporally associated with the use of a medicinal product?
• Which item is NOT a data element for expedited reports?
• Which document is listed as being located at both the investigator/institution and sponsor locations to reflect agreement on protocol/amendments and CRF?
• Which term identifies the formal approval by the IRB to conduct the trial at the site?
• Which description best characterizes study endpoints?
• Which statement best represents a core purpose of the ICH E8 document?
• When should IRB/IEC decisions be made?
• To monitor adequately, monitors should be thoroughly familiar with which of the following?
• What describes the procedures for tracking the investigational products, including placebos and comparators?
• Prior to supplying investigational product to a trial site, what must the sponsor obtain?
• When preparing the clinical study report, what should the summary of the clinical database include?
• Who must notify the sponsor of serious adverse events and related reports?
• To document that there are written agreements among involved parties, which location is used?
• Which statement correctly reflects confidentiality of records in publications?
• Which of the following best reflects Phase IV objectives related to patient populations?
• Which term is a written description of a trial/study of any therapeutic, prophylactic, or diagnostic agent conducted in human subjects, in which the clinical and statistical description, presentations, and analyses are fully integrated into a single report?
• What role do designated medical personnel play in the trial?
• Which is NOT a standard toxicology heading under nonclinical studies?
• Which term refers to the written evaluation provided by the sponsor's auditor summarizing the audit results?
• Which term refers to an independent body responsible for protecting rights, safety, and well-being of human subjects by reviewing, approving, and providing continuing review of trial protocols and informed consent documents?
• Which statement best describes the focus of the Therapeutic Use category?
• Which term describes a sponsor-organized group that coordinates the conduct of a multicenter trial?
• Which trial type has a rationale and design that rests on earlier work, and should have clear and precise objectives, though those objectives may not lead to simple tests?
• What is the primary purpose of the coding in blinded trials?
• Which statement best reflects a monitor's qualification responsibilities?
• If significant formulation changes are made during clinical development, what must be available prior to using the new formulation in clinical trials?
• Which term means prevention of disclosure, to other than authorized individuals, of a sponsor's proprietary information or of a subject's identity?
• Which role is designated and supervised by the investigator at the trial site to perform critical trial-related procedures?
• In a multicenter trial, who is primarily responsible for ensuring standardized data collection across sites?
• Which topic focuses on presenting data and identifying the subjects to be evaluated?
• Which statement best describes the purpose of maintaining randomization codes and code-breaking procedures?
• What should the summary of efficacy data include to support conclusions about a treatment's effect?
• Which document is used to document the financial agreement between the investigator/institution and the sponsor for the trial?
• In the context of Investigational Medicinal Products, which aspect should be well characterized in formulations used in clinical trials?
• Which term describes documents that permit evaluation of the conduct of a study and the quality of the data produced?
• What is required when data on the CRF is derived from source documents?
• Source Documents: What is the purpose of source documents in a clinical trial?
• Which aspect most directly ensures the scientific integrity and credibility of a clinical trial's data?
• If new information becomes available that may affect a subject's willingness to continue participation, who should be informed?
• What presentation is useful for safety and efficacy data across multiple trials by indications or subgroups?
• Which term is a written, dated, and signed agreement between two or more involved parties that sets out any arrangements on delegation and distribution of tasks and obligations and, if appropriate, on financial matters?
• Where should the finalized CRFs be kept after completion and which copy is retained by the sponsor?
• What should be addressed in the nonclinical pharmacokinetics section?
• What is the purpose of the sponsor notifying investigators of safety information?
• Which term best describes the formal opinion issued by an Independent Ethics Committee regarding trial ethics and participant safety?
• Post-study events refer to serious adverse events that occurred after completion of a clinical study. In such cases, who is typically responsible for reporting to the sponsor?
• Which document records that the investigator is informed in a timely manner of relevant information as it becomes available?
• Which data are considered source data in a GCP trial and should be recorded directly on the Case Report Form (CRF)?
• In Phase I, what is the primary objective?
• Who may be designated to maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s)?
• Which term denotes the protection of a sponsor's proprietary information and participant identities from unauthorized disclosure?
• Which statement describes monitoring guidance for procedures?
• The term used for the physical and mental well-being of the trial subjects is what?
• Interim analyses may lead to early stopping when which conditions are met?
• Which term refers to an individual or body authorized to consent on behalf of a prospective subject?
• Which document documents chronological enrollment of subjects by trial number?
• Adverse events and/or laboratory abnormalities identified as critical to safety evaluations should be reported to the sponsor according to what?
• What should be adequate to support the proposed clinical trial regarding the investigational product?
• Which document addresses the financial aspects of the trial?
• Noncompliance with protocol, SOPs, GCP, or regulatory requirements by an investigator or sponsor staff should lead to what action?
• What must be included in informing the subject about the trial?
• What should the Title Page potentially include according to the guidelines?
• What must be included in the justification for sample size?
• Which document is used to document that an audit was performed, if available?
• The protocol should include a description of the trial's type or design and what else?
• Which statement best describes IRB/IEC responsibilities?
• Which of the following best describes the Therapeutic Confirmatory objectives?
• Informing the subject's primary physician about participation is recommended under what condition?
• Which item should the sponsor obtain from the IRB/IEC to confirm GCP compliance?
• If the IRB/IEC terminates or suspends its approval, what should the investigator do?
• Interim or annual reports to regulatory authorities are typically provided by which party?
• Which ICH guideline covers the structure and content of clinical study reports?
• What should be described about the population to be studied?
• Why is blinded therapy case management included in expedited reporting guidelines?
• Interim analysis and early stopping are used to compare treatment arms with respect to what?
• In a clinical trial, which entity takes responsibility for initiation, management, and financing of the trial?
• Which statement best describes a monitor's responsibility regarding informed consent?
• Which statement reflects a data security requirement for electronic data handling?
• Post-study adverse events are typically reported by the investigator to the sponsor. true or false?
• In the Background Information section, which item provides details about the investigational product?
• In selecting a control group, which statement best describes acceptable comparisons?
• Annual progress report to whom?
• Quality assurance activities require written SOPs. Who is responsible for implementing and maintaining QA/QC systems with written SOPs?
• What is the purpose of maintaining a system for retrieving investigational products and documenting retrieval?
• Which element describes the route of administration, dosage, dosage regimen, and treatment periods?
• What does the term Investigator-Adequate Resources imply?
• What term refers to detailed, written instructions to achieve uniformity of the performance of a specific function?
• What are the purposes of trial monitoring?
• Which document confirms that all activities required for trial close-out are completed and copies of essential documents are filed?
• Which data are typically included under efficacy data in a clinical trial report?
• Which statement best describes how information in the Investigator's Brochure should be presented?
• Which term refers to the laws and regulations addressing the conduct of clinical trials of investigational products?
• After reporting a fatal or life-threatening ADR within 7 days, by when should a more complete report typically be provided?
• What term describes the pharmaceutical form of an active ingredient or placebo that is tested or used as a reference in a clinical trial?
• In the Effects in Humans: Introduction, which topics may be included when available?
• What ensures that each individual involved in conducting a trial is qualified by education, training, and experience to perform their task?
• Which statement best distinguishes Quality Control from Quality Assurance in GCP?
• Which term describes permission to examine records and reports that are important to evaluation of a clinical trial?
• Who is responsible for selecting investigators/institutions?
• What is the requirement for informing all persons assisting with the trial about the protocol and duties?
• Regulatory reporting of unexpected serious adverse drug reactions: to whom should these be reported?
• Which entity is authorized under applicable law to consent on behalf of a prospective subject to participate in the trial?
• Documentation of regulatory authorities' authorization/approvals/notifications required for protocol amendments and other documents should be kept by which parties?
• Which document records shipment dates, batch numbers, and the method of shipment for investigational products and trial-related materials, enabling tracking and accountability?
• Which document shows the IRB/IEC is constituted in accordance with GCP?
• Which document records the normal values and ranges for tests used in the protocol?
• A Therapeutic Confirmatory study primarily aims to do which?
• In multicenter trials, what should be provided when investigators collect additional data beyond the core protocol?
• Which action documents that the investigator or authorized staff confirms the observations recorded in the Case Report Form (CRF)?
• Which document describes how, in an emergency, the identity of blinded investigational product can be revealed without unblinding remaining subjects?
• What is a primary purpose of packaging for the investigational product?
• Clinical trials should be conducted in accordance with ethical principles originating from which source?
• Which term refers to any medical or dental facility where clinical trials are conducted?
• Who should retain records of the changes and corrections to CRFs?
• Which statement best describes medications permitted before and/or during the trial?
• What documentation identifies the IRB/IEC review and approval and notes the version number and date of documents?
• What statement best describes the purpose of direct access to source data and documents in GCP inspections?
• Which topic covers handling data gaps and unusual values in data?
• Which statement best reflects the requirement regarding coercion or undue influence in trial participation?
• Which document records the method for randomization of the trial population?
• Which member of the trial team is designated and supervised by the investigator at the trial site to perform critical trial-related procedures and/or to make important trial-related decisions?
• What term describes the planned and systematic actions to ensure trial activities comply with GCP and regulatory requirements?
• Phase III aims to complete the information needed to support what?
• Prior to the trial, what must be obtained regarding the consent forms?
• Which statement describes investigator obligations under 5.6.2 a-d?
• Which term describes an individual responsible for the conduct of the clinical trial at a site?
• In Phase I, which objective may be conducted as a secondary objective?
• Which statement best describes sponsor's audit purpose?
• Phase III typically includes further exploring which aspect in a broader population?
• Which statements best describes what is subject to expedited reporting for adverse drug reactions?
• What is a primary purpose of Phase IV studies?
• The Full Analysis Set is designed to approximate which principle?
• Which documentation category tracks certification, accreditation, QC, external QA, or other validation of procedures used in the protocol?
• Which scenario qualifies as a Serious Adverse Event (SAE)?